Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT05754840 Not yet recruiting - Cancer Clinical Trials

CANnabinoids in Pediatric ONCology

CAN-PONC
Start date: June 2023
Phase: Phase 1/Phase 2
Study type: Interventional

CANnabinoids in Pediatric ONCology is a randomized, double blind, adaptive clinical trial looking at the tolerability of cannabinoids in children with cancer across 3 Canadian children's hospitals.

NCT ID: NCT05754801 Not yet recruiting - Cancer Clinical Trials

Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine 'Coriolus Versicolor for improving the quality of life of patients with advanced-stage cancer. Subjects will be randomized into a treatment group or placebo group for 6 months.

NCT ID: NCT05748704 Recruiting - Cancer Clinical Trials

Metabolic and Immunological Effects of a Modified Fasting Regimen in Cancer Patients

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

This is a single-arm prospective pilot study assessing the metabolic and immunologic effects of a modified fasting regimen in cancer patients with different cancer types and concomitant anticancer treatment.

NCT ID: NCT05746169 Recruiting - Cancer Clinical Trials

Discovering Cancer Risks From Environmental Contaminants and Maternal/Child Health

Start date: September 1, 2021
Phase:
Study type: Observational

The DREAM Cohort is a longitudinal observational study developed to enhance our understanding of how multiple exposures to environmental chemicals and pollutants across a diverse population of pregnant women and their offspring are linked to cancer risks. Because pregnancy induces multiple maternal hormonal and physiological changes that can increase cancer susceptibility to environmental chemical exposures, this study will focus on pregnancy as a period of particular vulnerability to toxic agents.

NCT ID: NCT05745038 Not yet recruiting - Cancer Clinical Trials

A Single Arm Pilot Trial of a Social Network Intervention

SONATA
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to see if a social network support program (SOcial Networks to Activate Trust & Adherence or SONATA) is helpful for older individuals receiving cancer treatment. The SONATA program will last for about 4 months. There are a total of 6 coaching sessions. The first 5 sessions will be held approximately every 1 to 2 weeks. Session 6 or the final session will be held approximately 1 to 2 months after session 5. Each session will last for about 1 to 2 hours.

NCT ID: NCT05743491 Not yet recruiting - Cancer Clinical Trials

Yoga Versus Standard Care for Reducing Fatigue in Hispanic Cancer Survivors (YOCAS©®)

Start date: March 15, 2023
Phase: N/A
Study type: Interventional

This is a phase II 2-arm randomized controlled trial comparing yoga (Yoga for Cancer Survivors, YOCAS©®) to standard care in reducing cancer-related fatigue in Hispanic cancer survivors. Survivors randomized to Arm 1 will receive Standard Care and Arm 2 will receive standard care plus a four-week YOCAS©® intervention where Hispanic survivors attend yoga sessions together. Investigators will acquire preliminary data on cancer-related fatigue, as well as, secondary data on other common side effects.

NCT ID: NCT05741242 Enrolling by invitation - Cancer Clinical Trials

Basket Trial of Neoantigen Synthetic Long Peptide Vaccines in Patients With Advanced Malignancy

Start date: November 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a basket trial of neoantigen synthetic long peptide vaccines in patients with advanced malignancy. Up to 20 subjects will be treated with the neoantigen synthetic long peptide vaccines.

NCT ID: NCT05736731 Not yet recruiting - Cancer Clinical Trials

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

EVEREST-1
Start date: April 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression. The main questions this study aims to answer are: - Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients - Phase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: - Enrollment and Apheresis in BASECAMP-1 (NCT04981119) - Preconditioning Lymphodepletion (PCLD) Regimen - A2B530 Tmod CAR T cells at the assigned dose

NCT ID: NCT05734963 Recruiting - Cancer Clinical Trials

ORganoid GeneratioN Study for Cancer

ORIGINS
Start date: April 4, 2022
Phase:
Study type: Observational

ORIGINS - a multi-site sample collection study to establish patient-derived pre-clinical models for cancers

NCT ID: NCT05732922 Not yet recruiting - Cancer Clinical Trials

ORCHARD- Optimising Home Assessment of Rural Patients

ORCHARD
Start date: February 2023
Phase: N/A
Study type: Interventional

This project assesses feasibility of providing medically vulnerable rural patients with Medical-Self-Assessment-Boxes containing equipment to use at home during telephone and video consultations (telemedicine) with GPs and other healthcare professionals. COVID-19 has caused an upsurge in primary care telemedicine which the investigators believe can be sustained and optimized to make things better for medically vulnerable rural patients beyond the pandemic. The investigators will achieve this by equipping the participants to self-measure and report key clinical measurements (e.g. blood pressure, temperature, oxygen levels) during telemedicine consultations. Before conducting a major evaluation of the Medical-Self-Assessment-Box for medically vulnerable rural patients the investigators must establish three things: First, to show the investigators can issue a Medical-Self-Assessment-Box to medically vulnerable rural patients and enable them to use it properly. Second, to determine that patients can use the Medical-Self-Assessment-Box effectively during telemedicine consultations. Third, to show that it is possible to measure how well the Medical-Self-Assessment-Box is working by counting how often the boxes are being used and whether use is appropriate and helpful. The knowledge gained will provide the investigators with the information needed to develop a funding proposal to evaluate Medical-Self-Assessment-Boxes for medically vulnerable rural patients in the whole of the UK.